Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia

Pirtobrutinib (LOXO-305), a reversible inhibitor of Bruton’s tyrosine kinase (BTK), was designed as an alternative strategy to treat ibrutinib-resistant disease that develops due to C481 kinase domain mutations. The clinical activity of pirtobrutinib has been demonstrated in CLL, but the mechanism o...

Descripción completa

Detalles Bibliográficos
Autores principales: Aslan, Burcu, Kismali, Gorkem, Iles, Lakesla R., Manyam, Ganiraju C., Ayres, Mary L., Chen, Lisa S., Gagea, Mihai, Bertilaccio, Maria Teresa Sabrina, Wierda, William G., Gandhi, Varsha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123190/
https://www.ncbi.nlm.nih.gov/pubmed/35595730
http://dx.doi.org/10.1038/s41408-022-00675-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123190/
https://www.ncbi.nlm.nih.gov/pubmed/35595730
http://dx.doi.org/10.1038/s41408-022-00675-9

Ejemplares similares